article thumbnail

Hospitals face lowest readmission fines since 2014, analysis finds

Healthcare Dive

More than 2,200 hospitals will incur penalties, the lowest number in nearly a decade, as the CMS adjusted its calculations for the impact of the COVID-19 pandemic.

Hospitals 228
article thumbnail

Improper Medicare payments down $20.7B since 2014, CMS data show

Fierce Healthcare

since 2014, CMS data show. Improper Medicare payments down $20.7B Tue, 11/16/2021 - 07:15.

Medicare 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SCOTUS rejects UnitedHealth appeal of Medicare Advantage overpayment rule

Healthcare Dive

The justices declined to take up the case, leaving intact a lower court ruling that backed the 2014 CMS regulation requiring swift return of overpayments.

article thumbnail

Anthem plans to change name to Elevance

Healthcare Dive

Prior to 2014, the company was known as WellPoint. It's the second name change for Anthem in the past decade.

325
325
article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill of Health

Market dynamics of authorized generics in Medicaid from 2014 to 2020. Insulin products and patents in the USA in 2004, 2014, and 2020: a cross-sectional study. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020. JAMA Intern Med. 2023 Feb 13:e226787. Epub ahead of print. 2023 Feb 23.

Medicare 140
article thumbnail

Roundup: Altera's ANZ head promoted to APAC VP and more briefs

Healthcare It News

His responsibilities now include the Southeast Asian market where he has lived from 2008 to 2014 and held senior positions with leading healthcare IT companies like Wolters Kluwer and Carestream Health. 1M grant awarded to evaluate Orygen's digital mental health platform A University of Melbourne professor has received almost A$1.5

article thumbnail

Another Legislative Attempt to Revive Gene Patenting

Bill of Health

Utah 2014)) and the Court of Appeals for the Federal Circuit (774 F.3d 2014)) confirmed that Myriad’s patents covering naturally occurring DNA sequences, no matter how short, were ineligible for patent protection. The company proved to be wrong: both the federal district court in Utah (3 F. 3d 1213 (D. 3d 755 (Fed. Edinburgh), 750 F.3d